- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03241992
MyChart in Patients With Inflammatory Bowel Disease. (MyIBD)
Utility of MyChart for Improving Quality of Life and Patient Satisfaction in Patients With Inflammatory Bowel Disease.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study will be a single site randomized control trial.
Patients will be randomized into a control arm and intervention arm. At baseline the investigators will obtain demographic data, quality of life measures, and satisfaction with MyChart for those patients who are alrealy active portal users. The control arm will receive periodic messages through MyChart that are not specific to IBD. The intervention arm will receive more specific disease related information such as IBD educational information, reminders to take their medications, and reminders to get vaccinated. The intervention arm will also receive questionnaires that assess their mood (depression and anxiety). The investigators will then inform the primary gastroenterologist for those patients in whom mild, moderate or severe depression and anxiety is identified. At the end the study, in both groups investigators will measure quality of life as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), a validated questionnaire for measuring health-related quality of life in patients with Crohn's and Ulcerative Colitis. Secondary outcomes will include: Satisfaction with Mychart as measured by a MyChart satisfaction survey, time to referral to mental health provider for patients identified with mild, moderate, or severe depression, or anxiety (PROMIS Depression and Anxiety Questionnaires), and Vaccine uptake (using a simple yes/no questionnaire asking patients if they received Flu, PCV13 or PPSV23.
The findings of this study will allow future clinicians to better understand how a patient portal can be utilized as a tool for the management of patients with IBD. This findings may lead to increased physician and patient engagement with the MyChart patient portal.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 92118
- Boston Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men and Women 18 years and older with a diagnosis of Inflammatory Bowel Disease (Crohn's or Ulcerative Colitis, or Indeterminate Colitis by standard criteria) who are scheduled for an upcoming appointment at the outpatient gastroenterology clinic or infusion unit.
Exclusion Criteria:
- Non-English speaking patients
- Patients identified by their physicians as being too cognitively impaired to participate
- Patients without access to computer with internet
- Patients not expected to be in the study area for the duration of the study such as patients only seen for a one time second opinion
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: MyChart Intervention
Subjects in the control arm will be enrolled in MyChart during the consent process and receive MyChart Disease Specific targeted IBD information and reminders as well as mood questionnaires.
At week 2 subjects will receive reminders to get vaccinated with another reminder sent at 3 months.
At month 1, subjects will receive the Promis Adult Short Form questionnaires for depression and anxiety through MyChart.
If a subject is identified as having mild, moderate or a severe mood disorder a message will be sent to their gastroenterologist with a recommendation to discuss the results with the patient and to consider a referral to mental health services.
Subjects will also receive educational information about IBD every 6 weeks along with reminders to take their medications.
|
Subjects receive targeted IBD information and reminders as well as mood questionnaires.
|
Kein Eingriff: Usual Care
Subjects in the control arm will be enrolled in MyChart during the consent process if they are not previously enrolled.
Enrollment in MyChart will provide them with access to their medical record and the ability to send or receive messages with their gastroenterologist or any other providers they see at our institution.
For patients with IBD it is standard practice to discuss medication adherence, vaccinations, and their mood at each appointment.
Subjects will receive generic, non-IBD related messages through MyChart.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Quality of life based on the SIBDQ
Zeitfenster: 6 months
|
Quality of life will be measured using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) which is a 10 item health-related quality of life (HRQoL) tool measuring physical, social, and emotional status (scores can range from 10-70, poor to good HRQoL).
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Satisfaction with MyChart
Zeitfenster: 6-months
|
The 14 item embedded MyChart Satisfaction Survey will be used to measure satisfaction.
Responses for 12 of the questions are answered on a scale of 0 to 10 where 10=Strongly Agree, 5=Neither Agree nor Disagree, and 0=Strongly Disagree, so the higher the score for those questions the greater the satisfaction.
there is also a question about the number of times myChart was used and an open-ended comments question..
|
6-months
|
Influenza vaccine uptake
Zeitfenster: 6-months
|
To measure vaccine uptake for flu the patients will be asked if they received the flu shot in the previous year.
A chart review will be done to confirm the self reported information.
|
6-months
|
Pneumococcal pneumonia (PCV13, PPSV23) vaccine uptake
Zeitfenster: 6-months
|
To measure PCV13, PPSV23 vaccine uptake for pneumococcal pneumonia the patients will be asked if they received the vaccine in the previous year.
A chart review will be done to confirm the self reported information.
|
6-months
|
Time to Referral for Behavioral Health
Zeitfenster: 6-months
|
After a patient has been identified as having anxiety or depression and a message has been sent to their healthcare provider the time it takes the provider to refer the patient to behavioral health will be measured.
|
6-months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Jason Reich, MD, Boston Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- H-35695
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Entzündliche Darmerkrankungen
-
Arkansas Children's Hospital Research InstituteEunice Kennedy Shriver National Institute of Child Health and Human Development...BeendetSIRS (Systemic Inflammatory Response Syndrome)Vereinigte Staaten
-
University of ArkansasBeendetPädiatrische Patienten mit SIRS (Systemic Inflammatory Response Syndrome)Vereinigte Staaten
Klinische Studien zur MyChart Disease Specific
-
Yale UniversityNational Library of Medicine (NLM)Noch keine RekrutierungPersönliche Gesundheitsinformationen | Inhaftierte PersonenVereinigte Staaten
-
The Cleveland ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AbgeschlossenChronisches NierenleidenVereinigte Staaten
-
NYU Langone HealthAbgeschlossen
-
Sunnybrook Health Sciences CentreAbgeschlossenStimmungsschwankungen | Bipolare StörungKanada
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)AbgeschlossenInfektionen der Atemwege | Grippe | ImpfungenVereinigte Staaten
-
Children's Hospital of Eastern OntarioRekrutierungDiabetes mellitus, Typ 1Kanada
-
AHS Cancer Control AlbertaTom Baker Cancer CentreRekrutierungBrustkrebs | DarmkrebsKanada
-
University of California, DavisRekrutierungLungenkrebsVereinigte Staaten
-
University of ChicagoAbgeschlossenDepression | Depressive Störung, MajorVereinigte Staaten
-
University of FloridaNational Center for Advancing Translational Sciences (NCATS)Noch keine RekrutierungFettleibigkeit | Ventrale Hernie